Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05697406 · ClinicalTrials.gov registry record · Phase 1
HP Pyruvate MRI in Cancers
A Phase 1 study of Tumors and Image, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05697406 is a Phase 1 study of Tumors and Image that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 25 participants, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05697406, a Phase 1 study of Tumors and Image, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
Study Locations (1)
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05697406
The ClinicalTrials.gov registry entry for NCT05697406 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (87% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT05697406 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05697406 about?
NCT05697406 is a clinical study titled "HP Pyruvate MRI in Cancers". Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruv...
What is the current status of trial NCT05697406?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-06-24. Estimated completion is 2028-12-01.
What conditions does trial NCT05697406 study?
This clinical trial studies the following conditions: Tumors, Image, Warburg Effect.
What interventions are being tested in trial NCT05697406?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG).
Who is sponsoring clinical trial NCT05697406?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05697406 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.